{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-04T06:11:12.342216+00:00","company":{"ticker":"CCEL","cik":862692,"company_name":"CRYO CELL INTERNATIONAL INC"},"pagination":{"limit":100,"returned":3,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"exchange_compliance_notice","fact_key":"129e84cf0c2c6e11a34ec716fc439494ebe4b31b","cik":862692,"ticker":"CCEL","company_name":"CRYO CELL INTERNATIONAL INC","filed_at":"2026-05-08T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"extension_granted","cure_deadline":"2027-09-09","deficiency_type":"other","delisting_effective_date":null,"exchange":"nyse_american","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2026-05-06","notice_type":"extension_granted","plan_due_date":"2026-04-08","raw_rule_text":null,"reported_value":null,"rule_numbers":[],"rules_cited_in_text":false},"claim":"CRYO CELL INTERNATIONAL INC received a nyse_american extension granted notice regarding other.","evidence_excerpt":"May 6, 2026, Cryo-Cell International, Inc. (the \"Company”) received a written notice from NYSE Regulation stating that it had accepted the Company’s plan to regain compliance with the continued listing standards of the N","confidence":0.75,"filing_url":"https://secwatch.observer/filing/0001193125-26-214569","anchor_url":"https://secwatch.observer/filing/0001193125-26-214569#claim-129e84cf0c2c6e11a34ec716fc439494ebe4b31b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/862692/000119312526214569/0001193125-26-214569-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"7d73500704e9b89c8e9b700426bfebe8d7cfc97f","cik":862692,"ticker":"CCEL","company_name":"CRYO CELL INTERNATIONAL INC","filed_at":"2026-03-12T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"plan_due","cure_deadline":null,"deficiency_type":"stockholders_equity","delisting_effective_date":null,"exchange":"nyse_american","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2026-03-09","notice_type":"deficiency_notice","plan_due_date":"2026-04-08","raw_rule_text":"Section 1003 (a) of the NYSE American Company Guide","reported_value":null,"rule_numbers":["1003(a)"],"rules_cited_in_text":true},"claim":"CRYO CELL INTERNATIONAL INC received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)).","evidence_excerpt":"March 9, 2026, Cryo-Cell International, Inc. (“Cryo-Cell”) received a written notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003 (a) of the NYSE American Company Guide. The Notice has no immediate effect on the listing or trading of the Company’s common stock, which will continue to trade on the NYSE American under the symbol “CCEL” while the Company pursues a plan to regain compliance.  In accordance with NYSE American procedures, the Company intends to submit a plan of","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-104392","anchor_url":"https://secwatch.observer/filing/0001193125-26-104392#claim-7d73500704e9b89c8e9b700426bfebe8d7cfc97f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/862692/000119312526104392/0001193125-26-104392-index.htm"},{"fact_type":"debt_financing","fact_key":"753b8678626f862381bd3d3218011ef8710038c1","cik":862692,"ticker":"CCEL","company_name":"CRYO CELL INTERNATIONAL INC","filed_at":"2025-10-23T23:59:59+00:00","payload":{"counterparty":"Susser Bank","effective_date":"2025-10-18","event":"amendment","instrument_type":"credit_facility","interest_rate_text":"Base Rate plus 4.25% for Term Loans, Base Rate plus 3.75% for Revolving Credit L","item_codes_triggered":["2.03"],"maturity_text":"October 18, 2027 for RCF Note; July 29, 2032 for Term Note","principal_text":"$8,000,000"},"claim":"CRYO CELL INTERNATIONAL INC amended credit facility of $8,000,000 with Susser Bank at Base Rate plus 4.25% for Term Loans, Base Rate plus 3.75% for Revolving Credit L maturing October 18, 2027 for RCF Note; July 29, 2032 for Term Note.","evidence_excerpt":"Date to October 18, 2027 and extended the Maturity Date of the Term Note to July 29, 2032. Revolving Credit Limit. The Amendment revised the revolving credit commitment to $8,000,000. Applicable Margin . The Amendment revised the Applicable Margin per annum as set forth below: Base Rate with respect to Term Loans Base Rate with respect to Revolving Credit","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-248883","anchor_url":"https://secwatch.observer/filing/0001193125-25-248883#claim-753b8678626f862381bd3d3218011ef8710038c1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/862692/000119312525248883/0001193125-25-248883-index.htm"}]}